CN1989131A - 取代的噻吩衍生物用作抗癌药 - Google Patents

取代的噻吩衍生物用作抗癌药 Download PDF

Info

Publication number
CN1989131A
CN1989131A CNA2005800105750A CN200580010575A CN1989131A CN 1989131 A CN1989131 A CN 1989131A CN A2005800105750 A CNA2005800105750 A CN A2005800105750A CN 200580010575 A CN200580010575 A CN 200580010575A CN 1989131 A CN1989131 A CN 1989131A
Authority
CN
China
Prior art keywords
thiophene
carboxylic acid
acid amides
pyrimidine
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800105750A
Other languages
English (en)
Chinese (zh)
Inventor
林晓东
A·里科
Y·周
A·B·杰弗森
A·瓦特
王小京
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NOVARTIS VACCINES and DIAGNOSTIC Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of CN1989131A publication Critical patent/CN1989131A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2005800105750A 2004-03-30 2005-03-30 取代的噻吩衍生物用作抗癌药 Pending CN1989131A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55834204P 2004-03-30 2004-03-30
US60/558,342 2004-03-30

Publications (1)

Publication Number Publication Date
CN1989131A true CN1989131A (zh) 2007-06-27

Family

ID=34972501

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800105750A Pending CN1989131A (zh) 2004-03-30 2005-03-30 取代的噻吩衍生物用作抗癌药

Country Status (11)

Country Link
US (2) US7470701B2 (https=)
EP (1) EP1732919A1 (https=)
JP (1) JP2007531757A (https=)
CN (1) CN1989131A (https=)
AU (1) AU2005228899A1 (https=)
BR (1) BRPI0508230A (https=)
CA (1) CA2561977A1 (https=)
IL (1) IL177799A0 (https=)
MX (1) MXPA06010520A (https=)
RU (1) RU2006138036A (https=)
WO (1) WO2005095386A1 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102844320A (zh) * 2010-02-17 2012-12-26 武田药品工业株式会社 杂环化合物
CN104262289A (zh) * 2014-10-09 2015-01-07 武汉大学 一种苯并噻唑衍生物及其抗肿瘤用途
CN104603130A (zh) * 2012-04-13 2015-05-06 Epizyme股份有限公司 人类组蛋白甲基转移酶ezh2抑制剂的盐形式
CN109400595A (zh) * 2018-12-24 2019-03-01 深圳市第二人民医院 一类含噻吩环的抗癌化合物
WO2021032170A1 (zh) * 2019-08-20 2021-02-25 南京明德新药研发有限公司 用作Cdc7抑制剂的四并环类化合物
CN114644582A (zh) * 2022-04-11 2022-06-21 中原工学院 一种苯基双硫脲类化合物的制备方法

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6881741B2 (en) * 2001-06-11 2005-04-19 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of Flavivirus infections
US8329924B2 (en) * 2001-06-11 2012-12-11 Vertex Pharmaceuticals (Canada) Incorporated Compounds and methods for the treatment or prevention of Flavivirus infections
KR101058696B1 (ko) * 2002-12-10 2011-08-22 바이로켐 파마 인코포레이티드 후라비바이러스 감염의 치료 또는 예방을 위한 화합물과방법
TW200533357A (en) * 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
JP2007519753A (ja) * 2004-01-30 2007-07-19 スミスクライン ビーチャム コーポレーション 化合物
US20080194561A1 (en) * 2005-07-26 2008-08-14 Jerry Leroy Adams Compounds
WO2007016292A2 (en) * 2005-07-27 2007-02-08 Vertex Pharmaceuticals Incorporated Heterocyclic amides as biofilm modulators
US7803806B2 (en) 2005-11-03 2010-09-28 Sgx Pharmaceuticals, Inc. Pyrimidinyl-thiophene kinase modulators
WO2007084391A2 (en) * 2006-01-18 2007-07-26 Amgen Inc. Thiazole compounds as protein kinase b ( pkb) inhibitors
EP2474546A1 (en) 2006-01-23 2012-07-11 Vertex Pharmaceuticals Inc. Thiophene-carboxamides useful as inhibitors of protein kinases
BRPI0709680B8 (pt) * 2006-03-27 2021-05-25 Nerviano Medical Sciences Srl derivados de pirrol, tiofeno e furano substituídos por piridil e piridimil como inibidores de quinase
WO2007120760A2 (en) * 2006-04-13 2007-10-25 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
WO2007139816A2 (en) * 2006-05-23 2007-12-06 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
WO2007139795A1 (en) * 2006-05-23 2007-12-06 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
JP5290186B2 (ja) * 2006-11-15 2013-09-18 ヴァイロケム ファーマ インコーポレイテッド フラビウイルス感染症の治療または予防用のチオフェン類似体
UY30892A1 (es) * 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
AU2012233017B2 (en) * 2007-02-07 2013-01-10 Novartis Ag Inhibitors of Akt activity
US8420690B2 (en) * 2007-02-07 2013-04-16 Glaxosmithkline Llc Inhibitors of Akt activity
DE102007010801A1 (de) 2007-03-02 2008-09-04 Bayer Cropscience Ag Diaminopyrimidine als Fungizide
EP2173728A2 (en) 2007-07-17 2010-04-14 Amgen Inc. Heterocyclic modulators of pkb
US7919504B2 (en) * 2007-07-17 2011-04-05 Amgen Inc. Thiadiazole modulators of PKB
HRP20151052T1 (xx) 2007-07-19 2015-11-06 H. Lundbeck A/S Peteroäślani heterocikliäśki amidi i srodne tvari
PL2201012T3 (pl) * 2007-10-11 2014-11-28 Astrazeneca Ab Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b
US9029411B2 (en) 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
TWI426074B (zh) * 2008-04-30 2014-02-11 Nerviano Medical Sciences Srl ５－（２－胺基－嘧啶－４－基）－２－芳基－１ｈ－吡咯－３－羧醯胺之製造方法
EP2303852A4 (en) * 2008-06-26 2011-12-28 Glaxosmithkline Llc ACTIVITY INHIBITORS AKT
US20110098221A1 (en) * 2008-06-26 2011-04-28 Hong Lin INHIBITORS OF Akt ACTIVITY
EP2161259A1 (de) 2008-09-03 2010-03-10 Bayer CropScience AG 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CN102405047B (zh) 2009-01-30 2014-07-09 葛兰素史密斯克莱有限责任公司 结晶型的n-{(1s)-2-氨基-1-[(3-氟苯基)甲基]乙基}-5-氯-4-(4-氯-1-甲基-1h-吡唑-5-基)-2-噻吩甲酰胺盐酸盐
WO2010090716A1 (en) 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
WO2010101302A1 (en) 2009-03-05 2010-09-10 Takeda Pharmaceutical Company Limited Thienopyrimidine as cdc7 kinase inhibitors
AU2010276441B2 (en) * 2009-07-21 2015-07-02 Gilead Sciences, Inc. Inhibitors of Flaviviridae viruses
WO2011031669A1 (en) 2009-09-09 2011-03-17 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
US8524764B2 (en) 2010-01-15 2013-09-03 Gilead Sciences, Inc. Inhibitors of Flaviviridae viruses
MX2012008211A (es) 2010-01-15 2012-08-08 Gilead Sciences Inc Inhibidores de virus flaviviridae.
US8859768B2 (en) 2010-08-11 2014-10-14 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
TW201217365A (en) 2010-08-11 2012-05-01 Millennium Pharm Inc Heteroaryls and uses thereof
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
TW201307309A (zh) 2010-10-13 2013-02-16 Millennium Pharm Inc 雜芳基化合物及其用途
PT2734515E (pt) 2011-07-13 2016-03-11 Gilead Sciences Inc Derivados de ácido tiofen-2-carboxílico úteis como inibidores de vírus flaviviridae
TWI490221B (zh) * 2011-08-15 2015-07-01 Takeda Pharmaceutical 雜環化合物
JPWO2013161871A1 (ja) * 2012-04-25 2015-12-24 興和株式会社 Ｔｌｒ阻害作用を有するチオフェン誘導体
US8841340B2 (en) 2012-08-17 2014-09-23 Gilead Sciences, Inc. Solid forms of an antiviral compound
US8759544B2 (en) 2012-08-17 2014-06-24 Gilead Sciences, Inc. Synthesis of an antiviral compound
US8927741B2 (en) 2012-08-17 2015-01-06 Gilead Sciences, Inc. Synthesis of an antiviral compound
WO2014177982A1 (en) * 2013-04-30 2014-11-06 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
WO2017007756A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc Hetero-halo inhibitors of histone deacetylase
CN108602776B (zh) * 2015-09-18 2021-12-03 默克专利有限公司 用作irak抑制剂的杂芳基化合物及其用途
WO2017063966A1 (en) * 2015-10-13 2017-04-20 Bayer Pharma Aktiengesellschaft Substituted 2-(1h-pyrazol-1-yl)-benzothiazole compounds
EP3388428B1 (en) * 2015-12-07 2021-08-04 Suzhou Sinovent Pharmaceuticals Company Five-membered heterocyclic amides wnt pathway inhibitor
EP3418275B1 (en) * 2016-02-16 2021-03-17 Korea Institute of Science and Technology Novel 2,3,5-substituted thiophene compound as protein kinase inhibitor
HUE057849T2 (hu) 2017-01-11 2022-06-28 Alkermes Inc Hiszton deacetiláz biciklusos gátlói
GB201712567D0 (en) 2017-08-04 2017-09-20 Karin & Sten Mortstedt Cbd Solutions Ab Selective ligands for tau aggregates
LT3664802T (lt) 2017-08-07 2022-06-27 Alkermes, Inc. Bicikliniai histonų deacetilazės inhibitoriai
GB201807147D0 (en) 2018-05-01 2018-06-13 Oncologica Uk Ltd Therapeutic combination
KR20210143783A (ko) * 2019-02-28 2021-11-29 케자르 라이프 사이언스 단백질 분비 저해제로서 티아졸 유도체
CN115536648B (zh) * 2021-06-29 2024-09-17 深圳开悦生命科技有限公司 一类抑制rna解旋酶dhx33的多环化合物及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3908012A (en) * 1970-10-05 1975-09-23 Pfizer Arylpyrimidines-inhibitors of platelet aggregation and bronchodilators
US5731315A (en) * 1995-06-07 1998-03-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted sulfonic acid n- (aminoiminomethyl)phenylalkyl!-azaheterocyclamide compounds
US6034093A (en) * 1995-06-07 2000-03-07 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted sulfonic acid N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
US6080767A (en) * 1996-01-02 2000-06-27 Aventis Pharmaceuticals Products Inc. Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
US6399656B1 (en) * 1998-07-28 2002-06-04 Smithkline Beecham Corporation Compounds and methods
AU5379900A (en) 1999-06-07 2000-12-28 Shire Biochem Inc. Thiophene integrin inhibitors
WO2001062233A2 (en) 2000-02-25 2001-08-30 F. Hoffmann La Roche Ag Adenosine receptor modulators
JP2002037784A (ja) * 2000-05-17 2002-02-06 Nikken Chem Co Ltd 新規チオフェンアミド化合物
DE10034623A1 (de) * 2000-07-17 2002-01-31 Bayer Ag Heterocyclisch substituierte Pyridine als Cytokin-Inhibitoren
AU2002338642A1 (en) 2001-04-13 2002-10-28 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
FR2827603B1 (fr) * 2001-07-18 2003-10-17 Oreal Composes derives de diaminopyrazole substitues par un radical heteroaromatique et leur utilisation en teinture d'oxydation des fibres keratiniques
US6897220B2 (en) * 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
JP2005509645A (ja) * 2001-10-30 2005-04-14 ファルマシア・コーポレーション 炎症処置用のヘテロ芳香族カルボキサミド誘導体
JP4394959B2 (ja) 2002-04-08 2010-01-06 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性の阻害剤
GB0209715D0 (en) * 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
US7119111B2 (en) * 2002-05-29 2006-10-10 Amgen, Inc. 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use
GB0215650D0 (en) * 2002-07-05 2002-08-14 Cyclacel Ltd Bisarylsufonamide compounds
WO2004013130A1 (en) * 2002-08-02 2004-02-12 Argenta Discovery Limited Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors
AR043057A1 (es) * 2002-10-30 2005-07-13 Vertex Pharma Compuestos derivados de piridintiazoles como inhibidores de la quinasa rock y otras proteinas quinasa
DK1603570T5 (da) * 2003-02-26 2013-12-09 Sugen Inc Aminoheteroarylforbindelser som proteinkinaseinhibitorer
GB0308466D0 (en) * 2003-04-11 2003-05-21 Novartis Ag Organic compounds
TW200533357A (en) * 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
JP2007519753A (ja) * 2004-01-30 2007-07-19 スミスクライン ビーチャム コーポレーション 化合物

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102844320B (zh) * 2010-02-17 2016-03-23 武田药品工业株式会社 杂环化合物
CN102844320A (zh) * 2010-02-17 2012-12-26 武田药品工业株式会社 杂环化合物
CN108358899A (zh) * 2012-04-13 2018-08-03 Epizyme股份有限公司 人类组蛋白甲基转移酶ezh2抑制剂的盐形式
CN104603130A (zh) * 2012-04-13 2015-05-06 Epizyme股份有限公司 人类组蛋白甲基转移酶ezh2抑制剂的盐形式
CN104603130B (zh) * 2012-04-13 2018-04-27 Epizyme股份有限公司 人类组蛋白甲基转移酶ezh2抑制剂的盐形式
CN108358899B (zh) * 2012-04-13 2021-07-27 Epizyme股份有限公司 人类组蛋白甲基转移酶ezh2抑制剂的盐形式
CN104262289B (zh) * 2014-10-09 2016-06-08 武汉大学 一种苯并噻唑衍生物及其抗肿瘤用途
CN104262289A (zh) * 2014-10-09 2015-01-07 武汉大学 一种苯并噻唑衍生物及其抗肿瘤用途
CN109400595A (zh) * 2018-12-24 2019-03-01 深圳市第二人民医院 一类含噻吩环的抗癌化合物
CN109400595B (zh) * 2018-12-24 2020-07-17 深圳市第二人民医院 一类含噻吩环的抗癌化合物
WO2021032170A1 (zh) * 2019-08-20 2021-02-25 南京明德新药研发有限公司 用作Cdc7抑制剂的四并环类化合物
CN114644582A (zh) * 2022-04-11 2022-06-21 中原工学院 一种苯基双硫脲类化合物的制备方法
CN114644582B (zh) * 2022-04-11 2024-03-29 中原工学院 一种苯基双硫脲类化合物的制备方法

Also Published As

Publication number Publication date
CA2561977A1 (en) 2005-10-13
US20080255120A1 (en) 2008-10-16
JP2007531757A (ja) 2007-11-08
IL177799A0 (en) 2006-12-31
RU2006138036A (ru) 2008-05-10
MXPA06010520A (es) 2007-03-26
EP1732919A1 (en) 2006-12-20
US20050256121A1 (en) 2005-11-17
US7470701B2 (en) 2008-12-30
BRPI0508230A (pt) 2007-07-17
WO2005095386A1 (en) 2005-10-13
AU2005228899A1 (en) 2005-10-13

Similar Documents

Publication Publication Date Title
CN1989131A (zh) 取代的噻吩衍生物用作抗癌药
EP1633740B1 (en) 5-(acylamino)indazole derivatives as kinase inhibitors
TWI394749B (zh) 具有激酶抑制劑活性之雜戊環
US7157476B2 (en) Aminofurazan compounds useful as protein kinase inhibitors
JP5188988B2 (ja) ベンゾアゾール誘導体、組成物、及びオーロラキナーゼ阻害剤としての使用方法
CN100357278C (zh) 作为激酶抑制剂的取代的三唑二胺衍生物
US8183240B2 (en) Heteroaryls and uses thereof
US8470820B2 (en) Nitrogen-containing heteroaryl derivatives
US20100331315A1 (en) Rhodanines and related heterocycles as kinase inhibitors
US20090325925A1 (en) Thiophenes and uses thereof
CN101605782A (zh) 作为药物、药物组合物和特别地作为ikk抑制剂的2-苯胺基-4-杂芳基嘧啶的衍生物及其制备
NZ550114A (en) Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators
CN104098551A (zh) 作为欧若拉激酶抑制剂的取代喹唑啉类衍生物
JP7066644B2 (ja) がんの処置のための化合物および組成物
US8796314B2 (en) Heteroaryls and uses thereof
CN112521336B (zh) 一种吲唑类、吡咯并吡啶类化合物及其应用
JP2009538305A (ja) プロテインキナーゼのインヒビターとして有用なチオフェンカルボキサミド
US20060205740A1 (en) Chemical compounds
CN105008346B (zh) 作为磷酸二酯酶10（pde-10）抑制剂的嘧啶衍生物
CN102046605A (zh) 作为酪氨酸激酶调节剂用于治疗肿瘤的二氢吡唑衍生物
CN101189243A (zh) 取代的杂环及其作为chk1、pdk1和pak抑制剂的应用
HK1125631B (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: NOVARTIS VACCINES & DIAGNOSTIC

Free format text: FORMER OWNER: CHIRON CORP.

Effective date: 20080530

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20080530

Address after: Delaware

Applicant after: Novartis Vaccines & Diagnostic Inc.

Address before: American California

Applicant before: Chiron Corporation

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20070627